Lunai Bioworks Inc. has announced a strategic partnership with American Defense International, Inc. $(ADI)$ to enhance U.S. government efforts in developing countermeasures against chemical and biological threats. This collaboration aims to leverage Lunai's AI-enabled biomedical data platforms to accelerate the identification and testing of protective and therapeutic responses to hazardous agents such as sarin nerve gas. By integrating Lunai's advanced technological capabilities with ADI's expertise in defense and national security, the partnership seeks to bolster national preparedness against emerging threats. David Weinstein, CEO of Lunai, emphasized the importance of using technology to protect human health amidst rising geopolitical instability. Van Hipp, Chairman of ADI, highlighted the potential of Lunai's technology to rapidly discover and deploy lifesaving interventions, underscoring the critical nature of time and precision in such scenarios.